Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Insider Dianne C. Whitfield Sells 2,315 Shares

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) insider Dianne C. Whitfield sold 2,315 shares of the business’s stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total value of $107,161.35. Following the transaction, the insider now owns 50,751 shares of the company’s stock, valued at $2,349,263.79. This represents a 4.36 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Tarsus Pharmaceuticals Trading Up 0.7 %

Shares of Tarsus Pharmaceuticals stock opened at $49.91 on Friday. The company’s fifty day simple moving average is $48.54 and its 200-day simple moving average is $45.06. The company has a market cap of $1.92 billion, a price-to-earnings ratio of -13.10 and a beta of 1.05. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30. Tarsus Pharmaceuticals, Inc. has a 1 year low of $20.08 and a 1 year high of $57.28.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. The firm had revenue of $66.41 million for the quarter, compared to analyst estimates of $58.80 million. As a group, sell-side analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

Institutional Trading of Tarsus Pharmaceuticals

Several hedge funds have recently modified their holdings of the company. Summit Investment Advisors Inc. raised its position in Tarsus Pharmaceuticals by 6.8% in the 4th quarter. Summit Investment Advisors Inc. now owns 3,848 shares of the company’s stock valued at $213,000 after purchasing an additional 244 shares during the last quarter. Sherbrooke Park Advisers LLC grew its holdings in Tarsus Pharmaceuticals by 7.2% during the 4th quarter. Sherbrooke Park Advisers LLC now owns 6,571 shares of the company’s stock worth $364,000 after acquiring an additional 443 shares during the last quarter. Crowley Wealth Management Inc. acquired a new stake in Tarsus Pharmaceuticals in the 4th quarter valued at about $25,000. Bank of New York Mellon Corp raised its stake in shares of Tarsus Pharmaceuticals by 0.5% in the fourth quarter. Bank of New York Mellon Corp now owns 101,928 shares of the company’s stock worth $5,644,000 after acquiring an additional 498 shares during the last quarter. Finally, Swiss National Bank grew its stake in shares of Tarsus Pharmaceuticals by 1.2% during the fourth quarter. Swiss National Bank now owns 52,333 shares of the company’s stock valued at $2,898,000 after purchasing an additional 600 shares during the last quarter. Institutional investors and hedge funds own 90.01% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. Oppenheimer raised their price objective on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a research note on Wednesday, January 22nd. Jefferies Financial Group lifted their target price on Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a “buy” rating in a report on Thursday, March 6th. HC Wainwright reissued a “buy” rating and set a $73.00 target price on shares of Tarsus Pharmaceuticals in a research note on Wednesday, February 26th. Barclays decreased their target price on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating on the stock in a report on Wednesday, February 26th. Finally, Guggenheim reissued a “buy” rating and issued a $78.00 price target (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a research note on Monday, February 24th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $63.67.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.